Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT03282045
Other study ID # BOS_CS_01
Secondary ID
Status Completed
Phase Phase 3
First received
Last updated
Start date October 2016
Est. completion date May 24, 2018

Study information

Verified date March 2021
Source Bosnalijek D.D
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

The primary objective of this multicenter, single-blind, randomized, placebo-controlled, prospective, comparative study with parallel design and 4-arms is to evaluate superiority of Lysobact Complete Spray® against placebo and non inferiority of Lysobact Complete Spray® against active comparators (Tantum Verde® and Pharyngal®) in terms of efficacy based on the pain VAS scores evaluated by the patient using Sore Throat Pain Intensity Scale (STPIS).


Description:

This study will be conducted in approximately 3 centers in Bosnia Herzegovina and in 4 centers in Turkey. Primary objective: The primary objective of this study is to evaluate superiority of Lysobact Complete Spray® against placebo and non inferiority of Lysobact Complete Spray® against active comparators (Tantum Verde® and Pharyngal®) in terms of efficacy based on the pain VAS scores evaluated by the patient using Sore Throat Pain Intensity Scale (STPIS). Secondary objective(s): - Safety evaluation of Lysobact Complete Spray®, Tantum Verde® Spray, Pharyngal® Oromucosal Spray, based on the frequency and nature of adverse events occurring during treatment period. - Extent of change in difficulty in swallowing, evaluated on the basis of Difficulty in Swallowing Scale (DSS), on Day 2, Day 4 and Day 6, as compared with baseline. - Extent of change in swollen throat evaluation based on Swollen Throat Scale (STS) on Day 2, Day 4 and Day 6, as compared with baseline. - Change in frequency of study treatment applications on Day 2, Day 4 and Day 6, as compared with baseline. Test product: Lysobact Complete Spray® Active comparator product: Tantum Verde® Spray Active comparator product: Pharyngal® Oromucosal Spray Placebo product: Placebo Primary endpoint: • Primary endpoint is the change from baseline to Day 6 in mean VAS score for STPIS. Secondary endpoint(s): Secondary endpoints are as follows: - change from baseline to Day 6 in mean VAS score for DSS - change from baseline to Day 6 in mean VAS score for SwoTS - change from baseline to each visit (Day 2, Day 4, Day 6) for STPIS , DSS and SwoTS - percent improvement from baseline to each visit (Day 2, Day 4, Day 6) for STPIS , DSS and SwoTS - Incidence of adverse events and relationship to the study treatments - Incidence of serious adverse events and relationship to the study treatments Statistical methods: All patients who have received at least one dose of any study medication will be included in the safety evaluation (safety population). Patients who have completed all visits according to the protocol will be included in the efficacy population. The superiority and inferiority of Lysobact Complete Spray® will be tested in hierarchical order by the comparison of the mean change of VAS scores [Sore Throat Pain Intensity Scale (STPIS)] from baseline to Day 2, 4 and 6. Planned treatment duration is 5 days. Safety will be followed-up until Day 6. End of study is defined as the end of the follow up period for the last patient.


Recruitment information / eligibility

Status Completed
Enrollment 346
Est. completion date May 24, 2018
Est. primary completion date May 24, 2018
Accepts healthy volunteers No
Gender All
Age group 18 Years and older
Eligibility Inclusion Criteria: - Patients with acute tonsillo-pharyngitis symptoms in common cold and by using a scale-based symptom Tonsillo-Pharyngitis Assessment (TPA) as an objective finding of pharyngeal infection, with a score of =5 - Patients who will be treated only on a symptomatic treatment basis, and with a prescribed a oropharyngeal spray - Patients, 18 years of age and above, who provided an informed consent - Patients with a sore-throat of recent onset, symptoms initiated =48 hours - Patients with sore throat pain rated =66 mm on the Sore Throat Pain Intensity Scale (STPIS) - Patients with difficulty in swallowing rated =50 mm on Difficulty Swallowing Scale (DSS) - Patients with a sensation of swollen throat rated =33 mm on the Swollen Throat Scale (SwoTS) Exclusion Criteria: - Patients who had any previous (within 4 hours prior to screening examination) throat lozenge treatment/use - Patients who had used any flu-preparation which contains any analgesic ingredient such as paracetamol, ibuprofen or acetylsalicylic acid (ASA) along with a decongestant - Patients who had analgesic use (any) 4 hours prior to the screening examination - Patients who are prescribed an antibiotic use before the screening visit and are entitled to use antibiotics during the course of this non-interventional study - Patients with a known hypersensitivity to active/inactive ingredients of medications which is prescribed for the symptomatic treatment of sore throat - Patients with known hypersensitiveness to egg white and other allergens - Patients who are pregnant or breastfeeding

Study Design


Related Conditions & MeSH terms


Intervention

Drug:
Lysobact Complete Sprey
Inhaling spray
Tantum Verde® Spray
Inhaling spray
Pharyngal® Oromucosal Spray
Inhaling spray
Placebo
Inhaling spray

Locations

Country Name City State
Bosnia and Herzegovina University Clinical Center of the Republic of Srpska, ENT Clinic, Banja Luka, Bosnia and Herzegovina Banja Luka

Sponsors (2)

Lead Sponsor Collaborator
Bosnalijek D.D MonitorCRO

Country where clinical trial is conducted

Bosnia and Herzegovina, 

Outcome

Type Measure Description Time frame Safety issue
Primary to evaluate superiority of Lysobact Complete Spray® against placebo and non-inferiority of Lysobact Complete Spray® against active comparators The primary objective of this study is to evaluate superiority of Lysobact Complete Spray® against placebo and non-inferiority of Lysobact Complete Spray® against active comparators (Tantum Verde® and Pharyngal®) in terms of efficacy based on the pain VAS scores evaluated by the patient using Sore Throat Pain Intensity Scale (STPIS). Day 6
See also
  Status Clinical Trial Phase
Recruiting NCT04083417 - Sore Throat in Primary Care - a Comparison of Phenoxymethylpenicillin and no Antibiotic Treatment Phase 4
Not yet recruiting NCT03517215 - The Development and Testing of a Scaling Strategy for a Community-Based Primary Care Antimicrobial Stewardship Program N/A
Not yet recruiting NCT01782183 - Thermographic Characteristics of Sore Throat by Thermographic Camera N/A
Completed NCT02608788 - S.L. Spray Solution® and Difflam® and Acular®Spray for the Prevention of Postoperative Sore Throat Phase 4
Completed NCT01986361 - Placebo-Controlled Onset-of-Action Study of Flurbiprofen Utilizing the Double-Stopwatch Method Phase 3
Completed NCT01118533 - Impact of Blades Used for Scheduled Orotracheal Intubation on Postoperative Sore Throat N/A
Completed NCT03397797 - Effect of Intraoperative Neuromuscular Blockade on Postoperative Sore Throat and Hoarseness
Completed NCT01902641 - Muscle Relaxation for Short Procedures N/A
Completed NCT01444703 - Comparison of Licorice Versus Sugar-water Gargle for Prevention of Postoperative Sore Throat and Postextubation Coughing N/A
Completed NCT00957996 - Safety Study of IV Peramivir in Hospitalized Subjects With Confirmed or Suspected Influenza Phase 3
Completed NCT01033799 - Effect of the Consumption of a Fermented Milk on Common Infections in Shift-workers N/A
Completed NCT05069844 - Preoperative Gum Chewing for Different Durations to Prevent Sore Throat After Endotracheal Intubation N/A
Completed NCT05247333 - Implementation of a Minor Ailment Service in Community Pharmacy Practice N/A
Recruiting NCT03369132 - Efficacy of Natural Seawater Based Throat Spray in Acute Sore Throat Relief N/A
Completed NCT02682134 - Sore Throat Prevention Following Intubation Phase 4
Terminated NCT00958776 - A Study to Evaluate the Efficacy and Safety of IV Peramivir in Addition to Standard of Care Compared to Standard of Care Alone in Adults and Adolescents Who Are Hospitalized Due to Influenza Phase 3
Completed NCT00242281 - APC-111 MP Tablet Once a Day vs.Penicillin VK Four Times a Day Both for 10 Days in Patients With Strep Throat Phase 3
Completed NCT03729973 - Comparing Efficacy Preoperative Nebulized: Ketamine , Mgspo4 ,and Lidocaine In Attenuating Endotracheal Sore Throat Phase 3
Completed NCT04085744 - A Comparison Of Local Anesthetic Agents And Steroid On Tracheal Tube Cuff N/A
Completed NCT01506583 - Clinical Evaluation of QFlu Combo Test